Oral Piroxicam Versus Buccal Fentanyl in Breakthrough Pain
Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
100 patients with Breakthrough pain will be allocated to receive either oral prioxicam (OP)
(n=50) or sublingual fentanyl (SLF) (n=50) . Patients will be divided randomly into two equal
groups: oral prioxicam (OP) Group and sublingual fentanyl citrate (SLF) Group, comprising of
50 patients each.
Pain intensity level on a 0-10 visual analog scale (VAS), patients will be instructed about
the use of a 10-cm visual analog scale (VAS) (0 = no pain to 10 = worst possible pain).
frequency of Breakthrough pain throughout the day, onset of relief (0-5, 6-10, 11-15, or over
16 min), time required for dose titration, patient satisfaction and adverse effects were
assessed at 3, 7, 15, and 30 days after starting the treatment.